These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22583418)

  • 1. Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?
    Zhu Z; Shen Z; Xu C
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1081-7. PubMed ID: 22583418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted agents in second-line bladder cancer therapy.
    Gerullis H; Otto T; Ecke TH
    Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
    Fleischmann A; Thalmann GN; Perren A; Seiler R
    Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Signaling Transduction Pathways in Bladder Cancer.
    Abbosh PH; McConkey DJ; Plimack ER
    Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
    Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
    Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Krantz D; Hartana CA; Winerdal ME; Johansson M; Alamdari F; Jakubczyk T; Huge Y; Aljabery F; Palmqvist K; Zirakzadeh AA; Holmström B; Riklund K; Sherif A; Winqvist O
    Eur Urol; 2018 Dec; 74(6):688-692. PubMed ID: 30025882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics.
    Hutterer GC
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular signaling and the role of targeted therapies in bladder cancer.
    Black PC
    Minerva Urol Nefrol; 2012 Mar; 64(1):7-17. PubMed ID: 22402314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
    Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
    Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
    Ashrafizadeh M; Yaribeygi H; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):667-677. PubMed ID: 32013836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New directions for biologic targets in urothelial carcinoma.
    Richter S; Sridhar SS
    Mol Cancer Ther; 2012 Jun; 11(6):1226-35. PubMed ID: 22572812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bladder cancer: current and emerging strategies.
    Agarwal N; Hussain M
    Drugs; 2009 Jun; 69(9):1173-87. PubMed ID: 19537835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of anti-Her-2 therapy in bladder carcinoma.
    Marín AP; Arranz EE; Sánchez AR; Auñón PZ; Barón MG
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1915-20. PubMed ID: 20213094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
    Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
    Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.